Figure 5
Figure 5. CVF–induced AP and anti-OVA/OVA–induced classic pathway complement activation. Western blot analysis of C3 activation in wild-type (A) or properdin−/− (B) mouse serum. Cleavage product of the C3 α-chain was detected in serum treated with CVF in Mg2+-EGTA but not in untreated serum or serum treated with CVF in EDTA. (C) Densitometry of cleaved and intact C3 α-chain in panels A and B. (D) ELISA plate assays of anti-OVA/OVA–induced classic pathway complement activation in wild-type (WT), properdin−/−, and factor B knockout (fB−/−) mouse serum or in properdin−/− serum treated with an antihuman fB antibody.

CVF–induced AP and anti-OVA/OVA–induced classic pathway complement activation. Western blot analysis of C3 activation in wild-type (A) or properdin−/− (B) mouse serum. Cleavage product of the C3 α-chain was detected in serum treated with CVF in Mg2+-EGTA but not in untreated serum or serum treated with CVF in EDTA. (C) Densitometry of cleaved and intact C3 α-chain in panels A and B. (D) ELISA plate assays of anti-OVA/OVA–induced classic pathway complement activation in wild-type (WT), properdin−/−, and factor B knockout (fB−/−) mouse serum or in properdin−/− serum treated with an antihuman fB antibody.

Close Modal

or Create an Account

Close Modal
Close Modal